房颤患者停用口服抗凝药与缺血性卒中风险
基于英国和丹麦人群的巢式病例对照研究显示,房颤患者停用口服抗凝药(OAC)与缺血性卒中(IS)风险显著升高相关,总体OR为2.99(英国)和2.30(丹麦)。停用非维生素K拮抗剂口服抗凝药(NOAC)的风险更高(OR 4.59和3.37)。避免不必要的停药可能显著减少房颤相关卒中。
要点
- 房颤患者停用OAC后缺血性卒中风险增加约2-3倍。
- 停用NOAC的缺血性卒中风险高于停用维生素K拮抗剂。
- 停药时间长短和用药持续时间不影响上述风险关联。
核心结论
- 房颤患者停用OAC与缺血性卒中风险显著升高相关,总体风险增加约2-3倍。
研究设计与样本
- 基于英国初级保健电子健康记录(IQVIA Medical Research Data-UK)和丹麦南部地区登记数据的人群基础队列研究,采用巢式病例对照分析。
- 英国队列纳入76 882例房颤患者,丹麦南部地区队列纳入41 526例房颤患者,随访2016-2018年识别新发缺血性卒中病例。
- 缺血性卒中病例按年龄和性别匹配对照,使用逻辑回归计算停用OAC(对比当前使用OAC)的调整OR值。
主要发现
- 英国识别616例新发缺血性卒中,丹麦南部地区识别643例。
- 任何OAC停用的缺血性卒中OR:英国2.99(95% CI 2.31-3.86),丹麦2.30(95% CI 1.79-2.95)。
- 维生素K拮抗剂停用的OR:英国2.38(95% CI 1.72-3.30),丹麦1.83(95% CI 1.34-2.49)。
- 非维生素K拮抗剂口服抗凝药停用的OR:英国4.59(95% CI 2.97-7.08),丹麦3.37(95% CI 2.35-4.85)。
- OR值不受停药后时间及用药持续时间影响;每年英国最多987例、丹麦132例缺血性卒中可能通过不中断OAC治疗预防。
临床怎么用
- 临床应重视房颤患者OAC治疗的连续性,避免不必要的停药以降低缺血性卒中风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate associations between oral anticoagulant (OAC) discontinuation and risk of ischaemic stroke (IS) among patients with atrial fibrillation (AF). METHODS: We undertook a population-based cohort study with nested case-control analysis using UK primary care electronic health records (IQVIA Medical Research Data-UK) and linked registries from the Region of Southern Denmark (RSD). Patients with AF (76 882 UK, 41 526 RSD) were followed to identify incident IS cases during 2016-2018. Incident IS cases were matched by age and sex to controls. Adjusted ORs for OAC discontinuation (vs current OAC use) were calculated using logistic regression. RESULTS: We identified 616 incident IS cases in the UK and 643 in the RSD. ORs for IS with any OAC discontinuation were 2.99 (95% CI 2.31 to 3.86, UK) and 2.30 (95% CI 1.79 to 2.95, RSD), for vitamin K antagonist discontinuation they were 2.38 (95% CI 1.72 to 3.30, UK) and 1.83 (95% CI 1.34 to 2.49, RSD), and for non-vitamin K antagonist oral anticoagulant discontinuation they were 4.59 (95% CI 2.97 to 7.08, UK) and 3.37 (95% CI 2.35 to 4.85, RSD). ORs were unaffected by time since discontinuation and duration of use. Annually, up to 987 IS cases in the UK and 132 in Denmark could be preventable if OAC therapy is not discontinued. CONCLUSIONS: Our results suggest that patients with AF who discontinue OAC therapy have a significant twofold to threefold higher risk of IS compared with those who continue therapy. Addressing OAC discontinuation could potentially result in a significant reduction in AF-attributed IS.
引用
- García Rodríguez LA, Cea Soriano L, Munk Hald S, et al. Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke. Heart. 2020. PMID: 33310887. doi:10.1136/heartjnl-2020-317887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。